cladribine has been researched along with Lupus Erythematosus, Systemic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
| Cap, A; Delacruz, WP; Shumway, N | 1 |
| Bartkowiak, J; Biernat, W; Błoński, J; Kordek, R; Liberski, P; Robak, E; Robak, T | 1 |
| Robak, E; Sysa-Jedrzejowska, A; Wozniacka, A | 1 |
| McCune, WJ; Singer, NG | 1 |
| Kontogiannis, V; Lanyon, PC; Powell, RJ | 1 |
2 review(s) available for cladribine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
[Progress and perspectives in the treatment of systemic lupus erythematosus].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antineoplastic Agents, Alkylating; Azathioprine; Cladribine; Cyclophosphamide; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mycophenolic Acid; Vidarabine | 2005 |
Update on immunosuppressive therapy.
Topics: Adult; Arthritis, Juvenile; Azathioprine; Behcet Syndrome; Child; Cladribine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Granulomatosis with Polyangiitis; Humans; Hydroxychloroquine; Immunosuppressive Agents; Liver; Lung; Lung Injury; Lupus Erythematosus, Systemic; Methotrexate; Pemphigoid, Benign Mucous Membrane; Retina; Tacrolimus; Thalidomide | 1998 |
4 other study(ies) available for cladribine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |
Concomitant plasmapheresis and cladribine infusion for the treatment of life-threatening systemic lupus erythematosus.
Topics: Adult; Anemia, Aplastic; Cladribine; Humans; Lupus Erythematosus, Systemic; Male; Plasmapheresis | 2016 |
Langerhans cell histiocytosis in a patient with systemic lupus erythematosus: a clonal disease responding to treatment with cladribine, and cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clone Cells; Cyclophosphamide; Female; Histiocytosis, Langerhans-Cell; Humans; Immunoglobulin Heavy Chains; Immunohistochemistry; Immunophenotyping; Lupus Erythematosus, Systemic; Middle Aged; Salvage Therapy | 2002 |
Cladribine in the treatment of systemic lupus erythematosus nephritis.
Topics: Adult; Cladribine; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic | 1999 |